1 month Janux Therapeutics (NASDAQ:JANX) Receives New Coverage from Analysts at UBS GroupMarketBeat
UBS Group initiated coverage on Janux Therapeutics in a research note on Thursday. They issued a “buy” rating and a $69.00 price objective for the company.
X